Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced an agreement effective May 1, 2026, with a leading group purchasing organization (GPO) that provides coverage to approximately 35 million U.S. commercial lives, representing about 20% of the commercial market, for TONMYA (cyclobenzaprine HCl sublingual tablets). The agreement, which includes standard utilization management criteria, is a significant step in expanding patient access to the company's FDA-approved, non-opioid treatment for fibromyalgia.
Fibromyalgia affects millions of Americans, and TONMYA is the first new treatment for the condition in more than 15 years. The GPO agreement covers roughly 35 million lives, which is a substantial portion of the commercial insurance market. This move is expected to improve patient access to an alternative to opioid-based therapies, aligning with broader efforts to combat the opioid crisis by providing non-addictive pain management options.
Tonix is actively pursuing additional coverage across both commercial and government channels. The company already has existing Medicaid coverage in 38 states, representing approximately 55 million lives. The combination of the GPO agreement and existing Medicaid coverage positions Tonix to reach a significant portion of the U.S. population, potentially impacting the standard of care for fibromyalgia.
The implications for the industry are notable. TONMYA's entry into the market provides a new, non-opioid option for fibromyalgia management, potentially reducing reliance on opioids and their associated risks. For patients, this could mean access to a treatment with a different mechanism of action, offering hope for better symptom control. The GPO agreement also signals confidence from healthcare purchasing organizations in the value of TONMYA, which may encourage further adoption and coverage.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, the company's CNS commercial infrastructure supports its marketed acute migraine products, including Zembrace SymTouch and Tosymra. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, the company's pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, and immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention.
For investors, the GPO agreement is a positive development that could drive revenue growth and market penetration for TONMYA. The company's efforts to secure broad coverage may lead to increased prescription volumes and establish a strong foothold in the fibromyalgia treatment landscape. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The full press release can be viewed at https://ibn.fm/ShicX.
